{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:44:26Z","timestamp":1793285066544,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.addbeh.2024.108242","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T15:01:20Z","timestamp":1735830080000},"page":"108242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pharmacological treatment for substance use disorder: A systematic review"],"prefix":"10.1016","volume":"163","author":[{"given":"Joaqu\u00edn","family":"Mateu-Moll\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolom\u00e9","family":"P\u00e9rez-G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor Jos\u00e9","family":"Villanueva-Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addbeh.2024.108242_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/dar.13511","article-title":"Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials","volume":"42","author":"Acheson","year":"2023","journal-title":"Drug and Alcohol Review"},{"issue":"5","key":"10.1016\/j.addbeh.2024.108242_b0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms A Randomized Clinical Trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA International Medicine"},{"key":"10.1016\/j.addbeh.2024.108242_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103295","article-title":"Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis","volume":"97","author":"Bahji","year":"2021","journal-title":"International Journal of Drug Policy"},{"issue":"1","key":"10.1016\/j.addbeh.2024.108242_b0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1037\/pha0000550","article-title":"A Double-Blind, Randomized, Placebo-Controlled, Pilot Clinical Trial Examining Buspirone as an Adjunctive Medication During Buprenorphine-Assisted Supervised Opioid Withdrawal","volume":"31","author":"Bergeria","year":"2023","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.addbeh.2024.108242_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109074","article-title":"A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis","volume":"228","author":"Blevins","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1016\/j.addbeh.2024.108242_b0030","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/acer.14696","article-title":"Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in Alcohol Use Disorder","volume":"45","author":"Burnette","year":"2021","journal-title":"Alcohol, Clinical and Experimental Research"},{"issue":"2","key":"10.1016\/j.addbeh.2024.108242_b0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/acer.14768","article-title":"Naltrexone Moderates the Association of Alcohol Use and Affect Among Adolescent Drinkers in Daily Life","volume":"46","author":"Carpenter","year":"2022","journal-title":"Alcohol, Clinical and Experimental Research"},{"issue":"4","key":"10.1016\/j.addbeh.2024.108242_b0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ajad.12904","article-title":"Double blind placebo-controlled trial of galantamine for methadone-maintained individuals with cocaine use disorder: Secondary analysis of effects on illicit opioid use","volume":"28","author":"Carroll","year":"2019","journal-title":"American Journal of Addiction"},{"issue":"12","key":"10.1016\/j.addbeh.2024.108242_b0045","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1007\/s11606-019-05074-8","article-title":"Pharmacotherapy for Cocaine Use Disorder\u2014a Systematic Review and Meta-analysis","volume":"34","author":"Chan","year":"2019","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.addbeh.2024.108242_b0050","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1136\/bmj.m3934","article-title":"Treatment interventions to maintain abstinence from alcohol in primary care: Systematic review and network meta-analysis","volume":"371","author":"Cheng","year":"2020","journal-title":"British Medical Journal"},{"key":"10.1016\/j.addbeh.2024.108242_b0055","doi-asserted-by":"crossref","unstructured":"Collins, S. E., Duncan, M. H., Saxon, A. J., Taylos, E. M.,Mayberry, N., O Merrill, J., Hoffman, G. E., Clifasefi, S. L. & Ries, R. K. (2021). Combining behavioural harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial. The Lancet Psychiatry, 8(4), 287-300. https:\/\/doi.org\/0.1016\/S2215-0366(20)30489-2.","DOI":"10.1016\/S2215-0366(20)30489-2"},{"key":"10.1016\/j.addbeh.2024.108242_b0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jsat.2019.08.009","article-title":"Randomized Placebo-Controlled Trial of Galantamine in Individuals with Cocaine Use Disorder","volume":"107","author":"DeVito","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"11","key":"10.1016\/j.addbeh.2024.108242_b0065","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1007\/s00213-021-05925-5","article-title":"Effects of topiramate on the association between affect, cannabis craving, and cannabis use in the daily life of youth during a randomized clinical trial","volume":"238","author":"Emery","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.addbeh.2024.108242_b0070","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jpsychires.2024.08.044","article-title":"Results from a randomized controlled trial of zonisamide in the treatment of alcohol use disorder","volume":"179","author":"Farchione","year":"2024","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.addbeh.2024.108242_b0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2022.06.011","article-title":"A randomized controlled trial examining the effects of intranasal oxytocin on alcohol craving and intimate partner aggression among couples","volume":"152","author":"Flanagan","year":"2022","journal-title":"Journal of Psychiatric Research"},{"issue":"10","key":"10.1016\/j.addbeh.2024.108242_b0080","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial","volume":"7","author":"Freeman","year":"2021","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.addbeh.2024.108242_b0085","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/s41386-021-01055-w","article-title":"Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: A dose-response, randomized, controlled trial","volume":"46","author":"Garbutt","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.addbeh.2024.108242_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109606","article-title":"Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions","volume":"239","author":"Garel","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"12","key":"10.1016\/j.addbeh.2024.108242_b0095","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1001\/jamapediatrics.2019.3553","article-title":"Efficacy and Safety of Varenicline for Adolescent Smoking Cessation A Randomized Clinical Trial","volume":"173","author":"Gray","year":"2019","journal-title":"JAMA Pediatrics"},{"issue":"3","key":"10.1016\/j.addbeh.2024.108242_b0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1037\/pha0000252","article-title":"Naltrexone and Alcohol Effects on Craving for Cigarettes in Heavy Drinking Smokers","volume":"27","author":"Green","year":"2019","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/j.addbeh.2024.108242_b0105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41398-021-01478-5","article-title":"Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: A randomized trial","volume":"11","author":"Grodin","year":"2021","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.addbeh.2024.108242_b0110","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00213-022-06137-1","article-title":"The effects of nalmefene on the impulsive and reflective system in alcohol use disorder: A resting\u2011state fMRI study","volume":"239","author":"Grundinger","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.addbeh.2024.108242_b0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2021.06.003","article-title":"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study","volume":"52","author":"Guiraud","year":"2021","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.addbeh.2024.108242_bib311","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/1750984X.2019.1695141","article-title":"Questions and answers about conducting systematic reviews in sport and exercise psychology","volume":"13","author":"Gunnell","year":"2020","journal-title":"International Review of Sport and Exercise Psychology"},{"issue":"11","key":"10.1016\/j.addbeh.2024.108242_b0120","doi-asserted-by":"crossref","first-page":"e14594","DOI":"10.1111\/ijcp.14594","article-title":"The Effects of Pharmacological Interventions on Smoking Cessation in People with Alcohol Dependence: A Systematic Review and Meta-analysis of Nine Randomized Controlled Trials","volume":"75","author":"Guo","year":"2021","journal-title":"The International Journal of Clinical Practice"},{"key":"10.1016\/j.addbeh.2024.108242_b0125","doi-asserted-by":"crossref","unstructured":"Hashimoto, N., Habu, H., Takao, S., Sakamoto, S., Okahisa, Y., Matsuo, K., Takaki, M., Kishi, Y. & Yamada, N. (2022). Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: an exploratory analysis. Clinical Trial, 233, 109365. https:\/\/doi.org\/0.1016\/j.drugalcdep.2022.109365.","DOI":"10.1016\/j.drugalcdep.2022.109365"},{"key":"10.1016\/j.addbeh.2024.108242_b0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejim.2024.06.001","article-title":"Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes","volume":"127","author":"Johnson","year":"2024","journal-title":"European Journal of Internal Medicine"},{"key":"10.1016\/j.addbeh.2024.108242_b0135","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00213-021-05842-7","article-title":"Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder","volume":"238","author":"Karl","year":"2021","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.addbeh.2024.108242_b0140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40199-019-00282-3","article-title":"Treatment of amphetamine abuse\/use disorder: A systematic review of a recent health concern","volume":"27","author":"Khoramizadeh","year":"2019","journal-title":"DARU Journal of Pharmaceutical Sciences"},{"issue":"19","key":"10.1016\/j.addbeh.2024.108242_b0145","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Inside"},{"issue":"1","key":"10.1016\/j.addbeh.2024.108242_b0150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/npr2.12232","article-title":"Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial","volume":"42","author":"Kotajima-Murakami","year":"2022","journal-title":"Neuropsychopharmacology Reports"},{"key":"10.1016\/j.addbeh.2024.108242_b0155","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41386-020-00945-9","article-title":"Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder","volume":"46","author":"Kranzler","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.addbeh.2024.108242_b0160","doi-asserted-by":"crossref","first-page":"e0266142","DOI":"10.1371\/journal.pone.0266142","article-title":"Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials","volume":"17","author":"Lim","year":"2022","journal-title":"Plos ONE"},{"issue":"5","key":"10.1016\/j.addbeh.2024.108242_b0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1590\/1516-4446-2019-0753","article-title":"N-acetylcysteine as an adjunctive treatment for smoking cessation: A randomized clinical trial","volume":"42","author":"Machado","year":"2020","journal-title":"Brazilian Journal of Psychiatry"},{"issue":"8","key":"10.1016\/j.addbeh.2024.108242_b0170","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/acer.14648","article-title":"Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder","volume":"45","author":"Mariani","year":"2021","journal-title":"Alcohol: Clinical and Experimental Research"},{"key":"10.1016\/j.addbeh.2024.108242_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108366","article-title":"Quetiapine treatment for cannabis use disorder","volume":"218","author":"Mariani","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2024.108242_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.111063","article-title":"Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder","volume":"255","author":"McCann","year":"2024","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2024.108242_b0185","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/ntr\/ntz170","article-title":"Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults","volume":"2020","author":"McClure","year":"2020","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1016\/j.addbeh.2024.108242_b0190","article-title":"Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers","volume":"255","author":"McClure","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2024.108242_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109111","article-title":"Varenicline as a Treatment for Cannabis Use Disorder: A Placebo-Controlled Pilot Trial","volume":"229","author":"McRae-Clark","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2024.108242_b0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13011-022-00493-z","article-title":"Correlates of treatment engagement and client outcomes: Results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder","volume":"17","author":"Mills","year":"2022","journal-title":"Substance Abuse Treatment, Prevention and Policy"},{"key":"10.1016\/j.addbeh.2024.108242_b0205","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/add.15417","article-title":"Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: A randomized placebo-controlled trial","volume":"116","author":"Mongeau-P\u00e9russe","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.addbeh.2024.108242_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108489","article-title":"Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network","volume":"130","author":"Montgomery","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.addbeh.2024.108242_b0215","first-page":"314","article-title":"The Modulatory Effects of Atomoxetine on Aberrant Connectivity During Attentional Processing in Cocaine Use Disorder","volume":"9","author":"Nestor","year":"2024","journal-title":"Biological Psychiatry: Cognitive Neuroscience and Neuroimaging"},{"issue":"12","key":"10.1016\/j.addbeh.2024.108242_b0220","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1111\/acer.14953","article-title":"Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels","volume":"46","author":"Nieto","year":"2022","journal-title":"Alcohol, Clinical and Experimental Research"},{"key":"10.1016\/j.addbeh.2024.108242_b0225","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1002\/brb3.2823","article-title":"The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial","volume":"13","author":"Padoei","year":"2022","journal-title":"Brain and Behavior"},{"key":"10.1016\/j.addbeh.2024.108242_b0230","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-022-06291-6","article-title":"Effects of baclofen on insular gain anticipation in alcohol\u2011dependent patients \u2014 a randomized, placebo\u2011controlled, pharmaco\u2011fMRI pilot trial","volume":"240","author":"Pelz","year":"2023","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.addbeh.2024.108242_b0235","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/adb.12747","article-title":"Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta\u2010analysis","volume":"24","author":"Ray","year":"2019","journal-title":"Addiction Biology"},{"key":"10.1016\/j.addbeh.2024.108242_b0240","article-title":"Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial","volume":"216","author":"Rizkallah","year":"2022","journal-title":"Pharmachology, Biochemistry and Behavior"},{"issue":"3","key":"10.1016\/j.addbeh.2024.108242_b0245","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/acer.14771","article-title":"Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder","volume":"46","author":"Robinson","year":"2022","journal-title":"Alcohol: Clinical and Experimental Research"},{"issue":"6","key":"10.1016\/j.addbeh.2024.108242_b0250","doi-asserted-by":"crossref","first-page":"e0234809","DOI":"10.1371\/journal.pone.0234809","article-title":"Treatment of stimulant use disorder: A systematic review of reviews","volume":"15","author":"Ronsley","year":"2020","journal-title":"Plos ONE"},{"issue":"1","key":"10.1016\/j.addbeh.2024.108242_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41397-021-00250-8","article-title":"Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: A randomized trial","volume":"22","author":"Schacht","year":"2022","journal-title":"Pharmacogenomics Journal"},{"issue":"8","key":"10.1016\/j.addbeh.2024.108242_b0260","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1007\/s00213-020-05540-w","article-title":"PPAR\u03b3 activation by pioglitazone does not suppress cravings for alcohol and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: A randomized controlled proof of principle study","volume":"237","author":"Schwandt","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.addbeh.2024.108242_b0265","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fphar.2022.1012433","article-title":"Pharmacological interventions on smoking cessation: A systematic review and network meta-analysis","volume":"13","author":"Shang","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.addbeh.2024.108242_b0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbb.2019.01.008","article-title":"Exogenous progesterone for cannabis withdrawal in women: Feasibility trial of a novel multimodal methodology","volume":"179","author":"Sherman","year":"2019","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"2","key":"10.1016\/j.addbeh.2024.108242_b0275","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/acer.13928","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder","volume":"43","author":"Sherwood","year":"2019","journal-title":"Alcohol: Clinical and Experimental Research"},{"key":"10.1016\/j.addbeh.2024.108242_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109054","article-title":"Citalopram for Treatment of Cocaine Use Disorder: A Bayesian Drop-The-Loser Randomized Clinical Trial","volume":"228","author":"Suchting","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1016\/j.addbeh.2024.108242_b0285","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.4314\/tjpr.v19i10.23","article-title":"Role of modafinil in the treatment of patients with methamphetamine dependence; An update on randomized, controlled clinical trial","volume":"19","author":"Tavakkoli","year":"2020","journal-title":"Tropical Journal of Pharmaceutical Research"},{"key":"10.1016\/j.addbeh.2024.108242_b0290","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13722-022-00345-y","article-title":"Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: Pilot trial feasibility and readmission rates","volume":"17","author":"Terasaki","year":"2022","journal-title":"Addiction Science & Clinical Practice"},{"issue":"2","key":"10.1016\/j.addbeh.2024.108242_b0295","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/wps.21073","article-title":"Substance use disorders: A comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention","volume":"22","author":"Volkow","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.addbeh.2024.108242_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.867878","article-title":"Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials","volume":"13","author":"Vuilleumier","year":"2022","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.addbeh.2024.108242_b0305","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/bcp.14271","article-title":"Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males\u2014a double-blinded, randomized study","volume":"86","author":"Weisshaar","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.addbeh.2024.108242_b0310","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41398-023-02410-9","article-title":"Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: Findings from a randomised clinical trial for the treatment of cannabis use disorder","volume":"13","author":"Ying-Heng","year":"2023","journal-title":"Translational Psychiatry"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460324002910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460324002910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:17:49Z","timestamp":1774336669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460324002910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":63,"alternative-id":["S0306460324002910"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2024.108242","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatment for substance use disorder: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2024.108242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108242"}}